- 1
- 2
SCA Hygiene
Sca Hygiene Healthcare division. Offers medtech incontinence solutions.Global presence in 90 markets. Expansion and growth priority.
Mike Hallerstrom, Senior Advisor Healthcare.
Mr MIKE HALLERSTROM
SENIOR ADVISORScottish Development International
Scottish Development International (SDI) is a government-funded organisation with a dedicated Life Sciences team which provides access to key Scottish product and service companies, together with expertise from the Scottish clinical and research base. SDI also works closely with many leading companies who have invested in Scotland as a European location.
Scotland is home to over 140 medical technology companies, ranging from major multinationals to smaller innovative home-grown companies.Scotland's sheer diversity in medtech offers opportunities for cooperation and collaboration.
Ms Mette Bach Dyremose
Nordic Business Development ExecutiveSEED Capital Denmark
SEED Capital is the largest early stage venture fund in Denmark. We invest in companies within Medtech and Technologies at the seed or even pre-seed stage from Denmark and southern Sweden. We invest in classic venture companies meaning companies that as a minimum will provide an opportunity for a 10x return on investment. The company should have a highly innovative solution and a scalable business model for entering an attractive market with a number of identified paths to exit.
Because of our strong partnership with the government funded innovation incubator DTU Symbion Innovation we are able to invest €250-750.000 at the early stages of a company’s development, allowing them an opportunity to prove their technology and business.
Depending on capital need, SEED Capital can invest up to €9 million in the following rounds – preferably in syndication with international investors. We take an active advisory role as an investor and will normally take the position of Chairman of the Board in the company until a skilled alternative is identified.
Mr Jon Ingi Benediktsson
Investment ManagerSelfdiagnostics OÜ
Selfdiagnostics is Estonian/German medtech company founded in 2008 with the purpose of developing NAAT (nucleic acid amplification technology) based POCT (point of care testing) platform and devices. The platform will be applicable for several human molecular diagnostics and prognostics purposes like testing for infectious diseases, genetic testing, personalized medicine related testing etc.
Selfdiagnostics holds “InTime” trade mark to sell Point of Care (POC) products in Europe
The mission, vision and purpose of the Selfdiagnostics OÜ and its subsidiary SelfD Technologie GmbH have been carried forward by a global paradigm shift in the area of healthcare. Facing an increase of healthcare expenses, an ageing society and the advent of the information society, governments and individuals are looking for ways to concentrate more on personal and preventive diagnostics to avoid potentially risky and expensive consequences. Easily accessible information about health, possible dangers to it and cures have raised people’s awareness, and in consequence the wish to deal with their possible health problems preventively, decisively and in time. Selfdiagnostics sees a challenge here to develop and introduce to the market products to prevent health problems that are economical and innovative in the sense of the population’s health, and effective in that of the economy.
Our mission is to evolve and offer innovative, user-friendly and discreet solutions to prevent health problems thereby building-up Selfdiagnostics as one of the worldwide innovation leaders in preventive medicine solutions.
The main values of the enterprise:
- To be responsible towards society
- To be customer-focused
- To be innovative and economical
- To be result-oriented
- To develop partnerships
Founders
The founders of the company are building the key people steering all corporate activities:
Marko Lehes MBA - CEO. Degree in physics, MBA in Entrepreneurship and Technology Development, experienced in leading large complex organization, investment management and tech transfer;
Indrek Tulp PhD - CSO. PhD in molecular technology, experienced in molecular design (Europe and USA);
Prof. Ülo Langel - Chairman of dept. of Neurochemistry, University of Stockholm; Adjunct Professor, The Scripps Research Institute; Adjunct Professor, Tartu University. Experienced in also biotech business development (exit in related field).
Partners and Advisors
The technology development and business development is strongly supported by:
- Fraunhofer IZI, (Germany) - Fraunhofer is Europe’s largest application-oriented research organization. There are significant synergies with the Institute's other projects, which might work in favor to development cost and timelines<
- Institute of Technology at University of Tartu (UT Institute of Technology), which is instrumental for the development of the isothermal DNA detection method, a core invention enabling the POC device. The institute has different groups led by highly recognized scientists experienced in the cooperation with other institutes and universities internationally, which published more than 30 papers in 2011/12 and owns 28 patents and patent applications. In the Institute there are all necessary contemporary biomedical facilities and a local network of clinics is providing samples and support if required.
- Helmut Kamlah PhD - advisor and consultant to Selfdiagnostics OÜ, having worked for 22 years in the diagnostic industry, finally as head of the POC division of Boehringer Mannheim/Hoffmann-La Roche
- Estonian Development Fund - an independent legal entity established by the Estonian Parliament which the statutory objective to invest state funds into early-stage knowledge and technology intensive start-ups
Technology and products
Selfdiagnostics OÜ is developing NAAT (Nucleic Acid Amplification Technology) based molecular diagnostics platform for POC devices.
Current platform is less complex, more rapid and discrete than other NAAT based platforms (including PCR), and significantly more sensitive, specific and user friendly than other serological platforms.
First device we plan to introduce to market is a rapid test for home-use (OTC) that is able to detect Chlamydia Trachomatis (CT) and Mycoplasma Genitalium (MG) from urine samples.
Business case
First product of Selfdiagnostics will be a NAAT based home-use quick test to detect sexually transmitted diseases (infections by Chlamydia Trachomatis (CT) and Mycoplasma Genitalium (MG)).
Similar rapid tests for home-use available on the market today are not convenient because they require invasive sample collection with swab sticks and many operations with several buffers and tubes.
NAAT based detection methods available on the market are lab-oriented and require complex instrumentation for detection and they still need professionals to operate them.
Selfdiagnostics is developing a platform and rapid tests for home-use to detect Chlamydia Trachomatis (CT) and Mycoplasma Genitalium (MG) with significant advantages:
- The test detects pathogenic DNA from crude urine without inconvenient and painful swab based sample collection
- The use of test does not need any instrumentation and can be performed by untrained individuals
- The accuracy of the new rapid test for home use is better than home use tests available on the market today.
Addressable market
The world market of POC Chlamydia tests sold into all customer segments is judged to be 378 mio Euro, thereof 114 mio Euro in Europe. The market is growing by approximately 7-8 %. It is expected, that OTC testing will grow significantly stronger than the testing in other market segments. Selfdiagnostics estimates the global accessible market in 2017 of 400 mio Euro, of which 25% can be reached by an innovative DNA detection method.
Competition: no existing products/producers utilize the same or a similar technology which provides the same value for the customer.
Competitive advantage: Unique value proposition, first mover, excellent development team and partners. Technology difficult to copy due to the combination of chemical and technical engineering challenges.
Sales channel and revenue model: sales via own web store and specialized distributors serving the OTC market; partnerships with leading global players in diagnostics.
Achievements
Assay |
Assay is working and providing reliable results under lab conditions |
Functional model |
1st iteration of functional model development has started |
Patents are pending |
“Method and rapid test device for the detection of target molecule” (submitted 29.1.2010 in the US and EU) “Isothermal nucleic acid amplification based on pathogen DNA detection from crude human biological samples” (submitted 20.9.2012 in the US) |
Ongoing activities
2013 - 2014 |
Functional model of device |
2015 |
Prototype, small series production |
2016 |
Clinical trials, approvals, production |
Please contact:
Marko Lehes
CEO/Founder
Marko.lehes@selfdiagnostics.eu
Phone: + 372 52 151 05
Mr Marko Lehes
CEOSensire Oy Ltd
Sensire Oy is a Finnish technology company specialized in wireless measuring and sensoring, logistics tracking and analytics with secure and scalable Cloud-service.
Sensire TempNet® Pharma-product is usable in medical industry with environmental monitoring and logistics tracking with wireless sensors used in cargo boxes, reception/delivery terminals and vehicles, in hospitals or pharmaceutical factories.
Solution ensure medicine safety from production or warehouse to distribution in hospital or other eq. medical facilities. Additional sensors can measure environmental variables, like temperature & harmful particles. One feature is to monitor bio samples taken from patients and securing item transportation and conditions from doctor’s reception to laboratory room.
Sensire's Pharma-solution offers technological excellence and own IPR, proven concept of service, security and archive, expandability with connectivity and global user access expansion possibility.
Mr Pekka Niskasaari
Director - Key Accounts & PartnershipsMr Jukkapekka Asikainen
CEOMs Miia Surakka
Sales & Marketing CoordinatorMr Matti Kuokkanen
VP SalesSGS Fimko Oy
SGS is the world's leading inspection, verification, testing and certification company.
We can take care of of all safety testing and certification needs of Medical Devices to access global markets.
Your efforts are supported by over 75.000 employees and over 1.500 offices and laboratories around the world. Your local service is provides by testing laboratories, technical experts and auditors in Helsinki, Espoo and Tampere.
In Finland only, our technical experts have over 150 years combined experience of working with Medical Devices. Today that experience is at your disposal.
When you need to be sure. SGS
Smartvisio Ltd.
Smartvisio care- and entertainment service runs on a cloud-based service platform which delivers communication and content services to the customers using standard audiovisual equipment – any standard TV and webcam are totally sufficient.
SOLARCH OY
Our mission is to encourage you and your family to take responsibility for your health and wellbeing. We do that by providing best-in-class online-service to organize and manage your and your family health and wellbeing information in one place and access it easily at your fingertips. We also support you to manage your or your love ones illnesses in the most effecient way.
The founder is Norwegian citizen living in Finland, a former NOKIA business director with 19 years experience in ICT and leadership. We have a great and energetic team including developers and advisors in health and wellbeing sectors in Finland and Scandinavia.